BioCentury
ARTICLE | Company News

Alphamab, 3DMed deal

March 14, 2016 7:00 AM UTC

3DMed and Alphamab partnered to develop and commercialize Alphamab’s KN035 to treat cancer, focusing on immunity against tumors. Both companies will be responsible for development, commercialization a...